atai Life Sciences increased its ownership interest in COMPASS Pathways from 19.4% to 20.8% indicating the potential of COMP360 in mental health care, post the recent COMP360 data in treatment-resistant depression.
Companies Featuredatai Life Sciences
atai Life Sciences is one of the biggest companies in the psychedelics field. The company aims to be a platform and has nine subsidiary companies working on everything from psilocybin for depression to DMT administration.
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.